Skip to search formSkip to main contentSkip to account menu

elisidepsin

Known as: L-Valine, N-((4S)-4-methyl-1-oxohexyl)-D-valyl-L-threonyl-L-valyl-D-valyl-D-prolyl-L-ornithyl-D-alloisoleucyl-D-allothreonyl-D-alloisoleucyl-D-valyl-L-phenylalanyl-(2Z)-2-amino-2-butenoyl-, (13-8)-lactone, 2,2,2-trifluoroacetate (1:1) 
A synthetic cyclic depsipeptide of the kahalalides family with potential antineoplastic activity. PM02734 is a derivative of a natural marine… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Depsipeptides

Narrower (2)

IrvalecPM02734

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors
This first-in-human, phase I clinical trial was designed to determine the dose-limiting toxicities (DLTs) and the dose for phase… 
2014
2014
Elisidepsin es un compuesto antitumoral de origen marino que causa muerte celular por necrosis relacionada con el contenido lipídico de las líneas celulares tumorales
Elisidepsin es un compuesto sintetico producido por PharmaMar S.A, derivado de un compuesto natural de origen marino. Tiene… 
2013
2013
IMAGE, a randomized phase Ib/II study of elisidepsin (E) as a single agent in pretreated advanced gastroesophageal (GE) cancer.
92 Background: E is a new marine compound with broad in vitro/in vivo antitumor activity. Low μM concentrations lead to cell… 
2012
2012
Phase I dose-finding and pharmacokinetic study of a combination of elisidepsin (E) and erlotinib (T) in patients (pts) with advanced solid tumors.
3093 Background: E is a new marine compound that has shown synergism with T in vitro even in T-resistant non-small-cell lung… 
2012
2012
ErbB 3 expression predicts sensitivity to elisidepsin treatment : In vitro synergism with cisplatin , paclitaxel and gemcitabine in lung , breast and colon cancer cell lines
Irvalec® (elisidepsin trifluoroacetate, PM02734) is a novel marine-derived cyclic peptide belonging to the Kahaladide family of… 
2012
2012
The mechanism of action of elisidepsin involves a direct hit on the plasma membrane
Background: Elisidepsin (PM02734, Irvalec ® ) is a synthetic compound whose structure is closely related to that of Kahalalide F… 
2012
2012
Study of the tumor sensitivity of the marine compound elisidepsin and her3 receptor in breast carcinomas
Elisidepsin es un nuevo depsipeptido sintetico resultante del programa de investigacion interna de PharmaMar para la obtencion de… 
2011
2011
Phase I study of elisidepsin (E) in combination with carboplatin (C) in patients (pts) with advanced solid tumors.
e13097 Background: E is a new synthetic depsipetide with broad in vitro/in vivo antitumor activity. E induces cell death through… 
2011
2011
IMAGE, a randomized phase Ib/II study of elisidepsin in pretreated advanced gastroesophageal cancer.
TPS169 Background: Elisidepsin (E) is a new marine compound with broad in vitro/in vivo antitumor activity. Cell exposure at low… 
2009
2009
Gateways to clinical trials.
[Methoxy-(11)C]PD-153035, 2-Methoxyestradiol; Adalimumab, Adecatumumab, Adefovir dipivoxil, ADH-1, ADX-10059, Aflibercept, AIR… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)